State Codes and Statutes

Statutes > Connecticut > Title17b > Chap319v > Sec17b-274a

      Sec. 17b-274a. Maximum allowable costs for generic prescription drugs. Implementation of maximum allowable cost list. The Commissioner of Social Services may establish maximum allowable costs to be paid under the Medicaid, state-administered general assistance, ConnPACE and Connecticut AIDS drug assistance programs for generic prescription drugs based on, but not limited to, actual acquisition costs. The department shall implement and maintain a procedure to review and update the maximum allowable cost list at least annually, and shall report annually to the joint standing committee of the General Assembly having cognizance of matters relating to appropriations and the budgets of state agencies on its activities pursuant to this section.

      (May 9 Sp. Sess. P.A. 02-1, S. 118; May 9 Sp. Sess. P.A. 02-7, S. 53; P.A. 04-76, S. 17.)

      History: May 9 Sp. Sess. P.A. 02-1 effective July 1, 2002; May 9 Sp. Sess. P.A. 02-7 required department to implement and maintain a procedure to review and update the maximum allowable cost list at least annually and to report annually to the General Assembly, effective August 15, 2002; P.A. 04-76 deleted reference to "general assistance".

      See Sec. 17b-491a re increasing cost efficiency of prescription drug programs.

State Codes and Statutes

Statutes > Connecticut > Title17b > Chap319v > Sec17b-274a

      Sec. 17b-274a. Maximum allowable costs for generic prescription drugs. Implementation of maximum allowable cost list. The Commissioner of Social Services may establish maximum allowable costs to be paid under the Medicaid, state-administered general assistance, ConnPACE and Connecticut AIDS drug assistance programs for generic prescription drugs based on, but not limited to, actual acquisition costs. The department shall implement and maintain a procedure to review and update the maximum allowable cost list at least annually, and shall report annually to the joint standing committee of the General Assembly having cognizance of matters relating to appropriations and the budgets of state agencies on its activities pursuant to this section.

      (May 9 Sp. Sess. P.A. 02-1, S. 118; May 9 Sp. Sess. P.A. 02-7, S. 53; P.A. 04-76, S. 17.)

      History: May 9 Sp. Sess. P.A. 02-1 effective July 1, 2002; May 9 Sp. Sess. P.A. 02-7 required department to implement and maintain a procedure to review and update the maximum allowable cost list at least annually and to report annually to the General Assembly, effective August 15, 2002; P.A. 04-76 deleted reference to "general assistance".

      See Sec. 17b-491a re increasing cost efficiency of prescription drug programs.


State Codes and Statutes

State Codes and Statutes

Statutes > Connecticut > Title17b > Chap319v > Sec17b-274a

      Sec. 17b-274a. Maximum allowable costs for generic prescription drugs. Implementation of maximum allowable cost list. The Commissioner of Social Services may establish maximum allowable costs to be paid under the Medicaid, state-administered general assistance, ConnPACE and Connecticut AIDS drug assistance programs for generic prescription drugs based on, but not limited to, actual acquisition costs. The department shall implement and maintain a procedure to review and update the maximum allowable cost list at least annually, and shall report annually to the joint standing committee of the General Assembly having cognizance of matters relating to appropriations and the budgets of state agencies on its activities pursuant to this section.

      (May 9 Sp. Sess. P.A. 02-1, S. 118; May 9 Sp. Sess. P.A. 02-7, S. 53; P.A. 04-76, S. 17.)

      History: May 9 Sp. Sess. P.A. 02-1 effective July 1, 2002; May 9 Sp. Sess. P.A. 02-7 required department to implement and maintain a procedure to review and update the maximum allowable cost list at least annually and to report annually to the General Assembly, effective August 15, 2002; P.A. 04-76 deleted reference to "general assistance".

      See Sec. 17b-491a re increasing cost efficiency of prescription drug programs.